MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (740)	9/25/2003 5:56:53 PM
From: Icebrg	Read Replies (2) of 2240

At the UBS conference DD mentioned that they (plus parnters) now have different 12 clinical programs running and that he expect an additional 3 before the year-end. Slowly but surely the pipeline starts to fill up. Erik - MDX-010 (Medarex) Melanoma, prostate cancer, breast cancer, HIV - MDX-060 (Medarex) CD30+ lymphomas - MDX-070 (Medarex) Prostate cancer (PSMA) - MDX-018 (Medarex) Autoimmune Disease (Co-dev with Genmab) - Osidem (IDM) Her-2+ Ovarian cancer - Humax-CD4 (Genmab) Psoriasis, Cutaneous T-cell Lymphoma - Humax-IL15 (Amgen) Rheumatoid Arthritis - Humax-EGFr (Genmab) Head and Neck cancer - CNTO 148 (Centocor/J&J) Anti-Inflammatory (Anti-TNFa) - CNTO 1275 (Centocor/J&J) Anti-Inflammatory (Anti-cytokine) - NVS Antibody (Novartis) Autoimmune Disease - 2nd NVS Antibody (Novartis) Autoimmune Disease -------------------------------------------------------------------------- Still to come this year: - EGF fusion protein - anti-anginogenesis product - colon cancer product.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next